Prohost Biotech
HomeArticlesProhost LettersProhost Letter #455
Prohost Letters
Premium

Prohost Letter #455

Prohost Letter #455 Introduction Our Prohost Letter disappeared for six months. Several reasons dictated our decision to temporarily halt its publication. The major reason was the devastating visit of...
P

Prohost Biotech

1 min read
36
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Tags

CRISPR Therapeutics (CRSP)
Intellia Therapeutics (NTLA)
Prohost Portfolio

Comments (0)

Please sign in to join the discussion

Related Articles

Prohost Letters
Premium

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ ( GILD ) stock price has been paralyzed for more than three consecutive years.  T...
P

Prohost Biotech

Aug 21, 2024

1m
68
Prohost Letters
Premium

Prohost Letter #460 ~ Treating IgA Nephropathy

Prohost Letter #460 Treating IgA Nephropathy Immunoglobulin A ( IgA ), the antibody of the immune system known to fight infections, can itself cause two important diseases. It can attack the body caus...
P

Prohost Biotech

Jun 1, 2024

1m
43
Prohost Letters
Premium

Prohost Letter #459 ~ NAFLD & NASH

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is Non-Alcoholic Steatohepatitis. We will start with NAFLD.   NAFLD The Non-Alcoholic Fatty Liver Disease is cau...
P

Prohost Biotech

Mar 3, 2024

1m
36